Latest From Genexine Inc.
The JV to be called JAGUAHR Therapeutics will focus on the AhR pathway. Simcere acquires Chinese rights to JW’s gout candidate.
Daiichi Sankyo also gets right of first negotiation for edaravone, approved in the US and Japan, in other Central and South American markets. Astellas advances its “Rx+” strategy in partnership with iota Biosciences.
In its first big pharma deal, Austrian biotech will develop experimental vaccines for Merck against an undisclosed target. Innovent licenses Chinese rights to Lilly diabetes candidate, while Novartis gets option to Iconic’s preclinical ophthalmology program.
The planned merger between Genexine and ToolGen, which was poised to create a major Korean biotech entity, has collapsed amid recent generally weak investor sentiment over the sector. But the two sides will maintain their collaborations for new drug development going forward, with a focus on gene and cell therapies.
- Large Molecule
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Immune Disorders
- Infectious & Viral Diseases
- Metabolic Disorders
- Genexine Co. Ltd.
- South Korea
- Pacific Rim
- Parent & Subsidiaries
- Genexine Inc.
- Senior Management
Young Chul Sung , PhD, CTO
Tae Kim, PhD, VP, Clin. Operations
Kyudon Kim, EVP, COO
- Contact Info
Phone: (82) 31 628 3200
700 Daewangpangyo-ro, Korea Bio Park
Bundang-gu, Seongnam-si,, 13488
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.